ArticleBMC infectious diseases2025
Metagenomic next-generation sequencing (mNGS) guides targeted antibiotic therapy and reduces mortality in sepsis: a propensity-matched retrospective cohort study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesTo evaluate the impact of metagenomic next-generation sequencing (mNGS)-guided antimicrobial therapy on mortality in patients with sepsis.
methodsA retrospective cohort study was conducted on 303 patients with sepsis admitted to the ICU between January 2021 and December 2022. Patients were divided into the mNGS group (93 cases) and the non-mNGS group (130 cases). The primary outcome was 28-day mortality. Statistical analysis included binary logistic regression, propensity score matching (PSM), and mediation analysis.
resultsA 1:1 PSM was performed for the original cohort (n = 303), yielding a matched cohort of 160 patients (n = 80 each group). In the matched cohort, antibiotics adjustments based on pathogenic results were more frequent and the 28-day mortality was lower in the mNGS group than in the non-mNGS group (P < 0.01). Binary logistic regression further confirmed significant associations of mNGS detection with a higher likelihood of antibiotic adjustment (odds ratio [OR] = 29.742, 95% CI [10.630, 83.170]) and shorter time to antibiotic adjustment (OR = 0.671, 95% CI [0.566, 0.795]), also with less skin and soft tissue infection (OR = 0.089, 95% CI [0.009, 0.880]) and abdominal infection (OR = 0.206, 95% CI [0.052, 0.812]). Each 1-point increase in the Sequential Organ Failure Assessment (SOFA) score was associated with a 16.9% higher risk of mortality (OR = 1.169, CI [1.054, 1.297]). The decision of antibiotic adjustment (OR = 0.252, CI [0.101, 0.627]) was negatively associated with 28-day mortality. The treatments of mechanical ventilation (OR = 4.260, CI [1.783, 10.181]) and continuous renal replacement therapy (CRRT) (OR = 4.253, CI [2.117, 8.541]) were positively related to the 28-day mortality. The mediation analysis indicated the total effect of mNGS detection on 28-day mortality was significant (Z = − 2.754, P = 0.006), while the indirect effect through antibiotics adjustment was not significant (Z = 0.367, P = 0.714).
conclusionThe mNGS detection facilitates antibiotic adjustment and is associated with reduced 28-day mortality in septic ICU patients. These findings highlight its potential for broader clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.